Organovo Holdings, Inc. (ONVO)
Chart Events
Performance Outlook
| Previous Close | 1.2200 |
| Open | 1.2100 |
| Bid | 1.1900 x 900 |
| Ask | 1.2000 x 800 |
| Day's Range | 1.1801 - 1.2299 |
| 52 Week Range | 1.0000 - 3.4000 |
| Volume | |
| Avg. Volume | 39,147 |
| Market Cap | 10.462M |
| Beta (5Y Monthly) | 0.88 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.0100 |
| Earnings Date | Nov 08, 2023 - Nov 12, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ONVO
Related Research
- Organovo Holdings, Inc.ARWR: Lowering target price to $28.00ARROWHEAD PHARMACEUTICALS IN has an Investment Rating of HOLD; a target price of $28.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.RatingFair ValueEconomic Moat5 days agoArgus Research
GlobeNewswireOrganovo to Participate in the H.C. Wainwright Global Investment Conference
SAN DIEGO, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with high fidelity in three-dimensional (3D) human tissues that recapitulate key aspects of human disease, today announced that Keith Murphy, Founder and Executive Chairman, will present a corporate update and hold meetings with institutional investors during the H.C. Wainwright 25th Annual Global Investment Co
GuruFocus.comIs Organovo Holdings (ONVO) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap
Unpacking the Financial Health of Organovo Holdings Inc (ONVO) to Determine Its Investment Viability
- GlobeNewswire
Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data
SAN DIEGO, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (Organovo), a clinical stage biotechnology company that is focused on developing novel human therapies with demonstrated function in high fidelity three-dimensional (3D) tissues that recapitulate key aspects of human disease, today announced more details about its clinical program for FXR314, an FXR agonist that has completed initial clinical trials. FXR314 is a drug with safety and tolerability after daily oral
